Logo

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front

Share this
Coherus

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front

Shots:

  • Coherus signs an agreement with Sandoz to divest its ophthalmology franchise which includes a lead asset Cimerli ((ranibizumab-eqrn) along with its supporting commercial infrastructure
  • As per the terms of the agreement, Coherus will receive an all-cash consideration of $170M as up front payment along with an additional amount for Cimerli product inventory & subject to customary working capital adjustments at the closing date. The transaction is expected to close by H1’24
  • Moreover, the divestiture also includes Coherus’ BLA for Cimerli, ophthalmology sales, select field reimbursement teams, Cimerli product inventory on hand & the access to proprietary commercial software

Ref: FORMYCON | Image: FORMYCON

Related News:- Formycon AG Reports Preliminary P-III Trial (MAGELLAN-AMD) Results FYB203, a Proposed Biosimilar to Eylea

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions